Karen Wilson Purchases 10,000 Shares of Serina Therapeutics (NYSEAMERICAN:SER) Stock

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Director Karen Wilson acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was bought at an average price of $1.77 per share, for a total transaction of $17,700.00. Following the acquisition, the director owned 10,000 shares of the company’s stock, valued at approximately $17,700. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Serina Therapeutics Trading Down 6.2%

SER opened at $1.80 on Thursday. The stock has a market capitalization of $27 million, a P/E ratio of -0.90 and a beta of 1.15. The business has a 50-day moving average of $1.97. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.18 and a current ratio of 4.18. Serina Therapeutics, Inc. has a 12 month low of $1.22 and a 12 month high of $7.92.

Serina Therapeutics (NYSEAMERICAN:SER) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.58) earnings per share (EPS) for the quarter.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.